Text Size
320 studies found for:    "Anaplastic oligodendroglioma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Conditions: Oligoastrocytoma, Mixed;   Anaplastic Oligodendroglioma
Intervention: Drug: Temozolomide
2 Not yet recruiting Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Conditions: Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention: Drug: Temozolomide
3 Active, not recruiting Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Intervention: Drug: imatinib mesylate
4 Recruiting Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Conditions: Astrocytoma;   Oligodendroglioma;   Oligoastrocytoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma;   Glioblastoma;   Brain Tumors;   Brain Cancer
Intervention:
5 Terminated Yoga Therapy in Treating Patients With Malignant Brain Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Recurrent Adult Brain Tumor
Interventions: Procedure: yoga therapy;   Other: questionnaire administration;   Procedure: quality-of-life assessment
6 Terminated Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Central Nervous System Germ Cell Tumor;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Grade III Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Meningeal Melanocytoma
Interventions: Drug: EF5;   Procedure: conventional surgery;   Procedure: positron emission tomography;   Radiation: fluorine F 18 EF5;   Other: pharmacological study
7 Recruiting Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Diffuse Astrocytoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma
Interventions: Procedure: biopsy;   Procedure: computed tomography;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy treatment planning/simulation;   Radiation: radiation therapy;   Procedure: magnetic resonance imaging;   Procedure: positron emission tomography;   Drug: fluorine F 18 fluorodopa
8 Recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Active, not recruiting Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: temsirolimus;   Drug: perifosine;   Procedure: therapeutic conventional surgery;   Genetic: fluorescence in situ hybridization;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis
10 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
11 Terminated Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Subependymoma
Interventions: Drug: etanidazole;   Procedure: conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Recruiting Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumor
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Biological: trebananib;   Drug: placebo administration;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Completed Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Primary Hepatocellular Carcinoma;   Adult Subependymoma;   Advanced Adult Primary Liver Cancer;   Advanced Malignant Mesothelioma;   Male Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Malignant Mesothelioma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage II Esophageal Cancer;   Stage II Pancreatic Cancer;   Stage III Esophageal Cancer;   Stage III Pancreatic Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
14 Recruiting Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Conditions: Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: trebananib;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Terminated
Has Results 		Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Conditions: Astrocytoma;   Glioma;   Oligodendroglioma
Interventions: Drug: Irinotecan Hydrochloride (HCI) Treatment;   Drug: Continued Irinotecan Hydrochloride (HCI) Treatment
16 Completed Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours
Condition: Oligodendrogliomas
Intervention:
17 Active, not recruiting Sorafenib in Newly Diagnosed High Grade Glioma
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Anaplastic Oligodendroglioma
Intervention: Drug: Sorafenib dose escalation
18 Recruiting Cellular Immunotherapy Study for Brain Cancer
Conditions: Gliomas;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Glioma;   Glioblastoma Multiforme;   Malignant Meningioma
Intervention: Drug: alloreactive CTL
19 Withdrawn Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
Conditions: Glioblastoma Multiforme;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Glioma
Intervention: Drug: enzyme-inducing anti-epileptic drugs
20 Recruiting Phase I/II Trial of the Safety, Tolerability, and Anti-tumor Efficacy of AXL1717 (Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma;   Anaplastic Ependymoma
Intervention: Drug: AXL1717
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years